ESMO 2025 – J&J brings a new Rybrevant use into the fold
After promising early data in head and neck, J&J plans a new phase 3, Origami-5.
M&A analysis: Genmab bucks the bargain basement trend
The group’s $8bn acquisition of Merus was the standout in the third quarter.
Pivotal study designs revealed
Keenly awaited trials of ficerafusp alfa, Trodelvy and divarasib materialise.
The month ahead: November’s upcoming events
Conferences ramp up, and ASH abstracts near.
Another vote of no-confidence in co-stimulated bispecifics
BioNTech and Genmab's acasunlimab is the latest 4-1BB project to stumble.
